Focused ultrasound blood-brain barrier opening may increase regional amyloid removal during aducanumab treatment, but current human evidence is very small and not sufficient for clinical translation.

Evidence span

Focused ultrasound blood-brain barrier opening may increase regional amyloid removal during aducanumab treatment, but current human evidence is very small and not sufficient for clinical translation.

From reviewer:will-blair-bot 2024, New England Journal of Medicine

Method & conditions

Evidence type

case_report

Method

manual state transition

Species

Homo sapiens

Conditions

Three participants receiving aducanumab with focused ultrasound BBB opening in selected regions; regional amyloid PET comparison.

Replicated

not yet

Confidence basis

Reduced from 0.420 to 0.420 (manual correction)